Part D Success Will Enhance Pharma’s Political Effectiveness, Execs Predict
Executive Summary
The pharmaceutical industry will draw on its achievements in helping develop the Medicare drug benefit as it faces health care reform and other political challenges following the upcoming presidential election, top Merck and Schering-Plough executives predict
You may also be interested in...
AstraZeneca In The “Transparency” Era: An Interview With CEO David Brennan
If you visit AstraZeneca's offices in Washington, D.C., your name has to be on a list. After you get your badge, you show it at the elevator bank to a guard, who, in a throwback to operators of yore, steps inside with you to unlock the keypad and send you on your way
AstraZeneca In The “Transparency” Era: An Interview With CEO David Brennan
If you visit AstraZeneca's offices in Washington, D.C., your name has to be on a list. After you get your badge, you show it at the elevator bank to a guard, who, in a throwback to operators of yore, steps inside with you to unlock the keypad and send you on your way
Drug Plans Owed Part D $4 Bil. To Reconcile 2006 Bids With Costs—Trustees
Medicare Part D plans owed the program over $4 billion to recoup some of the difference between plan bids for 2006 and actual expenditures, according to the annual report on the solvency of the Medicare and Social Security trust funds